| Literature DB >> 25679378 |
Bi-xia Huang1, Ming-fan Zhu2, Ting Wu1, Jing-ya Zhou1, Yan Liu1, Xiao-lin Chen1, Rui-fen Zhou1, Li-Jun Wang1, Yu-ming Chen1, Hui-lian Zhu1.
Abstract
BACKGROUND AND AIM: Previous studies have indicated that neck circumference is a valuable predictor for obesity and metabolic syndrome, but little evidence is available for fatty liver disease. We examined the association of neck circumference with fatty liver disease and evaluated its predictive value in Chinese adults.Entities:
Mesh:
Year: 2015 PMID: 25679378 PMCID: PMC4334519 DOI: 10.1371/journal.pone.0118071
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Characteristics of subjects with (FLD) and without (non-FLD) FLD (age-adjusted) (n = 4053).
| Women(n = 1617) | Men(n = 2436) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Variables | FLD | (n = 263) | non-FLD | (n = 1354) | FLD | (n = 790) | non-FLD | (n = 1646) | ||
| Continuous data | Mean | SD | Mean | SD | P1 | Mean | SD | Mean | SD | P1 |
| Age, years | 51.0 | 10.0 | 43.5 | 11.3 | <0.001 | 46.0 | 11.1 | 45.6 | 13.1 | 0.492 |
| Height, cm | 158.0 | 5.5 | 158.2 | 5.4 | 0.015 | 169.7 | 5.7 | 169.3 | 5.9 | 0.080 |
| Weight, kg | 63.16 | 9.06 | 55.42 | 7.37 | <0.001 | 76.31 | 9.17 | 67.35 | 8.86 | <0.001 |
| Neck circumference, cm | 34.15 | 2.40 | 32.13 | 2.05 | <0.001 | 38.79 | 2.36 | 36.72 | 2.23 | <0.001 |
| Waist circumference, cm | 84.29 | 8.52 | 74.72 | 8.11 | <0.001 | 92.23 | 7.16 | 83.66 | 7.99 | <0.001 |
| Hip circumference, cm | 96.80 | 6.42 | 92.08 | 5.59 | <0.001 | 99.66 | 5.52 | 95.00 | 5.45 | <0.001 |
| Body mass index, kg/m2 | 25.29 | 3.24 | 22.15 | 2.78 | <0.001 | 26.47 | 2.61 | 23.47 | 2.65 | <0.001 |
| Waist/hip ratio | 0.87 | 0.06 | 0.81 | 0.06 | <0.001 | 0.93 | 0.05 | 0.88 | 0.05 | <0.001 |
| Systolic blood pressure, mmHg | 130.7 | 19.5 | 116.3 | 17.3 | <0.001 | 129.6 | 16.1 | 122.8 | 15.9 | <0.001 |
| Diastolic blood pressure, mmHg | 78.4 | 10.8 | 71.6 | 10.3 | <0.001 | 82.0 | 11.7 | 76.4 | 11.0 | <0.001 |
| Triglycerides, mmol/L | 1.79 | 1.19 | 1.14 | 0.83 | <0.001 | 2.41 | 1.64 | 1.51 | 1.08 | <0.001 |
| Total cholesterol, mmol/L | 5.90 | 1.15 | 5.43 | 1.05 | <0.001 | 5.82 | 1.19 | 5.47 | 1.02 | <0.001 |
| High density lipoprotein, mmol/L | 1.37 | 0.33 | 1.55 | 0.38 | <0.001 | 1.15 | 0.28 | 1.29 | 0.38 | <0.001 |
| Low density lipoprotein, mmol/L | 3.65 | 0.98 | 3.27 | 0.92 | 0.004 | 3.61 | 0.99 | 3.46 | 0.95 | <0.001 |
| Fasting blood glucose, mmol/L | 5.32 | 1.22 | 4.81 | 0.62 | <0.001 | 5.36 | 1.47 | 4.94 | 1.02 | <0.001 |
| Blood uric acid, μmol/L | 272.2 | 79.4 | 215.0 | 64.2 | <0.001 | 359.0 | 85.7 | 314.0 | 74.8 | <0.001 |
| Apolipoprotein A, g/L | 1.31 | 0.33 | 1.39 | 0.40 | 0.002 | 1.17 | 0.36 | 1.20 | 0.29 | 0.073 |
| Apolipoprotein B, g/L | 0.99 | 0.23 | 0.87 | 0.23 | <0.001 | 1.00 | 0.24 | 0.93 | 0.30 | <0.001 |
| Apolipoprotein E, g/L | 47.26 | 14.66 | 42.28 | 12.38 | <0.001 | 48.87 | 16.40 | 40.69 | 12.64 | <0.001 |
| Aspartate transaminase | 22.0 | (20.0–27.0) | 20.0 | (17.0–22.0) | <0.001 | 26.0 | (22.0–33.0) | 22.0 | (22.0–26.0) | <0.001 |
| Alanine transaminase | 21.0 | (15.0–31.0) | 15.0 | (11.0–19.0) | <0.001 | 34.0 | (23.0–48.0) | 21.0 | (16.0–28.0) | <0.001 |
| γ-glutamyl transpeptidase | 24.0 | (18.0–34.5) | 17.0 | (13.0–22.0) | <0.001 | 44.0 | (30.8–65.0) | 27.0 | (20.0–39.0) | <0.001 |
| Categorical data | n | % | n | % | P2 | n | % | n | % | P2 |
| Diabetes | 20 | 7.60 | 27 | 1.99 | <0.001 | 83 | 10.51 | 59 | 3.58 | <0.001 |
| Overweight | 172 | 65.40 | 301 | 22.23 | <0.001 | 668 | 84.56 | 695 | 42.22 | <0.001 |
| Central obesity | 190 | 72.24 | 331 | 24.45 | <0.001 | 480 | 60.76 | 369 | 22.42 | <0.001 |
P 1: Covariance analysis adjusted for age
P 2: Wald chi-square test adjusted for age
3: Median (percentile 25, 75). Logarithmic transformation before analysis
4: Diabetes was defined as fasting plasma glucose (FPG) levels ≥7.0 mmol/L or by a self-reported history of diabetes confirmed by the doctor(s).
5: Overweight was defined as a BMI ≧24 kg/m2 for both genders.
6: Central obesity was defined as a waist circumference (WC)≧80 cm in women and ≧90 cm in men.
Odds ratios of FLD by quartiles of neck circumference.
| FLD n (%) | Model 1 (Age-adjusted) | Model 2 (Model 1+BMI) | Model 3 (Model 1+WC) | Model 4 (Model 1+ BMI+WC) | Model 5 (Model 1+BMI+WC+WHR) | |
|---|---|---|---|---|---|---|
| Women | ||||||
| Q1 (27.0–31.0) | 28 (5.7) | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Q2 (31.1–32.2) | 32 (9.8) | 1.67 (0.98–2.85) | 1.10 (0.64–1.92) | 1.08 (0.62–1.88) | 1.01 (0.58–1.76) | 1.03 (0.59–1.79) |
| Q3 (32.3–33.8) | 63 (15.0) | 2.58 (1.60–4.13) | 1.32 (0.79–2.19) | 1.25 (0.75–2.09) | 1.13 (0.67–1.90) | 1.17 (0.70–1.96) |
| Q4 (33.9–41.5) | 140 (36.7) | 7.70 (4.95–11.99) | 2.53 (1.50–4.27) | 2.29 (1.34–3.93) | 1.94 (1.12–3.36) | 2.09 (1.20–3.63) |
|
| <0.001 | <0.001 | <0.001 | 0.007 | 0.003 | |
| Men | ||||||
| Q1 (28.5–35.8) | 72 (11.4) | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Q2 (35.9–37.3) | 133 (22.3) | 2.23 (1.63–3.05) | 1.06 (0.76–1.48) | 1.12 (0.80–1.57) | 0.95 (0.68–1.34) | 0.99 (0. 70–1.40) |
| Q3 (37.4–39.0) | 237 (37.0) | 4.58 (3.42–6.14) | 1.49 (1.07–2.07) | 1.48 (1.06–2.06) | 1.19 (0.84–1.67) | 1.29 (0.92–1.83) |
| Q4 (39.1–50.1) | 348 (61.5) | 12.42 (9.22–16.74) | 2.04 (1.40–2.97) | 2.08 (1.43–3.03) | 1.45 (0.98–2.15) | 1.65 (1.11–2.45) |
|
| <0.001 | <0.001 | <0.001 | 0.015 | 0.002 | |
Model 1: adjusted for age;
Model 2: adjusted for age and BMI;
Model 3: adjusted for age and WC;
Model 4: adjusted for age, BMI and WC;
Model 5: adjusted for age, BMI, WC and WHR.
*: p<0.05 compared with Q1;
**: p<0.001 compared with Q1.
Fig 1Age-adjusted ORs of FLD according to joint classification of NC and other anthropometric measures.
Fig 2Mechanisms linking a hypertrophic neck with the development of fatty liver disease.